Daxdilimab
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alopecia Areata
Conditions
Alopecia Areata
Trial Timeline
Apr 27, 2022 → Jan 26, 2024
NCT ID
NCT05368103About Daxdilimab
Daxdilimab is a phase 2 stage product being developed by Amgen for Alopecia Areata. The current trial status is completed. This product is registered under clinical trial identifier NCT05368103. Target conditions include Alopecia Areata.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05430854 | Phase 2 | Terminated |
| NCT05368103 | Phase 2 | Completed |
Competing Products
20 competing products in Alopecia Areata
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Baricitinib | Eli Lilly | Phase 2 | 52 |
| CTP-543 | Sun Pharmaceutical | Phase 2/3 | 65 |
| CTP-543 | Sun Pharmaceutical | Phase 3 | 77 |
| Deuruxolitinib + Placebo | Sun Pharmaceutical | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 2/3 | 65 |
| Baricitinib 4 MG Oral Tablet | Eli Lilly | Approved | 85 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| minoxidil | Johnson & Johnson | Phase 3 | 77 |
| 5% Minoxidil + 2% Minoxidil | Johnson & Johnson | Phase 3 | 77 |
| Minoxidil + vehicle of 5% Minoxidil topical foam | Johnson & Johnson | Phase 2 | 52 |
| 5% Minoxidil Topical Foam + Vehicle Topical Foam | Johnson & Johnson | Phase 3 | 77 |
| Upadacitinib + Upadacitinib Placebo | AbbVie | Phase 3 | 77 |
| Upadacitinib + Placebo | AbbVie | Phase 3 | 77 |
| Secukinumab + Placebo | Novartis | Phase 2 | 52 |
| Ritlecitinib | Pfizer | Pre-clinical | 22 |
| LITFULO | Pfizer | Pre-clinical | 22 |
| Ritlecitinib | Pfizer | Pre-clinical | 22 |
| Ritlecitinib higher dose + Ritlecitinib lower dose + Placebo | Pfizer | Phase 3 | 76 |
| Ritlecitinib | Pfizer | Pre-clinical | 22 |